22
Mar
David Venables Gbola Amusa

David Venables presented to a full room of investors at the ARM Cell & Gene Therapy Investor Day in New York. Watch David's presentation below or view the pdf here.

05
Dec

Edinburgh, UK, 5th December 2018 / Synpromics is pleased to hear that its partner, uniQure (NASDAQ:QURE), has announced the incorporation of its promoter, developed by Synpromics, in a new preclinical research target. This follows recent positive data, presented at the ESGCT world congress, demonstrating that this highly selective liver promoter is at least eight times more potent than the current industry standard.

16
Nov
Synpromics Fast 50

Edinburgh, UK, 16th November 2018 / Synpromics, the leader in gene control, is delighted to announce that it has been ranked 12th in the Deloitte ‘UK Technology Fast 50’ at the annual awards ceremony in London last night.

13
Nov

A new video from Synpromics’ investor, Calculus Capital, discusses why they invest and how this has aided development of our synthetic promoter technology.

22
Oct

Sarah Haecker Meeks and David Venables enjoyed the sun in San Diego earlier this month for the annual ARM Cell & Gene Meeting on the Mesa. Nearly 1000 senior executives, key decision makers and scientists congregated to share recent developments and advance cutting edge research in cell and gene therapy. This year’s conference saw a noticeable uptick in interest in next generation gene medicines and strategies to improve current products in development.

Pages